Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Malekzadeh F, Gandomkar A, Malekzadeh Z, Poustchi H, Moghadami M, Fattahi MR, Moini M, Anushiravani A, Mortazavi R, Sadeghi Boogar S, Mohammadkarimi V, Abtahi F, Merat S, Sepanlou SG, Malekzadeh R. Malekzadeh F, et al. Among authors: malekzadeh z. Arch Iran Med. 2020 Aug 1;23(8):548-556. doi: 10.34172/aim.2020.58. Arch Iran Med. 2020. PMID: 32894967 Free article.
Correction: Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Malekzadeh F, Gandomkar A, Malekzadeh Z, Poustchi H, Moghadami M, Fattahi MR, Moini M, Anushiravani A, Mortazavi R, Sadeghi Boogar S, Mohammadkarimi V, Abtahi F, Merat S, Sepanlou SG, Malekzadeh R. Malekzadeh F, et al. Among authors: malekzadeh z. Arch Iran Med. 2021 Feb 1;24(2):166. doi: 10.34172/aim.2021.26. Arch Iran Med. 2021. PMID: 33636987 Free article.
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
Dehghan Manshadi SA, Merat S, Mohraz M, Rasoolinejad M, Sali S, Mardani M, Tabarsi P, Somi MH, Sedghi R, Tayeri K, Nikbin M, Karimi J, Sharifi AH, Kalantari S, Norouzi A, Merat D, Malekzadeh Z, Mirminachi B, Poustchi H, Malekzadeh R. Dehghan Manshadi SA, et al. Among authors: malekzadeh z. Int J Clin Pract. 2021 Aug;75(8):e14304. doi: 10.1111/ijcp.14304. Epub 2021 May 17. Int J Clin Pract. 2021. PMID: 33930223
Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial.
Merat S, Sharifi AH, Poustchi H, Hajiani E, Gharavi A, Karimi J, Mansour-Ghanaei F, Fattahi MR, Ahmadi L, Somi MH, Kalantari H, Ghadir MR, Sheikhesmaeili F, Baniasadi N, Sohrabi M, Moosavy S, Ziaee M, Zahedi MJ, Mokhtare M, Sali S, Sayad B, Afshar B, Bakhshipour A, Parsi A, Sharifian A, Amiriani T, Malekzadeh Z, Merat D, Ganji A, Rahmani-Samani F, Jamali R, Sofian M, Ghezlou M, Sohrabpour AA, Goshayeshi L, Valizadeh-Toosi SM, Eslami L, Maleki I, Hormati A, Shayesteh AA, Shayesteh E, Norouzi A, Abna Z, Janbakhsh A, Fakheri H, Minakari M, Sardarian H, Ghajary AFA, Fattahi-Abdizadeh M, Latifnia M, Roozbeh F, Agah S, Fakhrieh-Asl S, Nateghi-Baygi A, Fattahi B, Nateghi-Baygi H, Hill A, Malekzadeh R. Merat S, et al. Among authors: malekzadeh z. Clin Infect Dis. 2021 Jul 1;73(1):172. doi: 10.1093/cid/ciaa1768. Clin Infect Dis. 2021. PMID: 33857308 No abstract available.
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
Poustchi H, Majd Jabbari S, Merat S, Sharifi AH, Shayesteh AA, Shayesteh E, Minakari M, Fattahi MR, Moini M, Roozbeh F, Mansour-Ghanaei F, Afshar B, Mokhtare M, Amiriani T, Sofian M, Somi MH, Agah S, Maleki I, Latifnia M, Fattahi Abdizadeh M, Hormati A, Khoshnia M, Sohrabi M, Malekzadeh Z, Merat D, Malekzadeh R. Poustchi H, et al. Among authors: malekzadeh z. J Gastroenterol Hepatol. 2020 Sep;35(9):1590-1594. doi: 10.1111/jgh.14994. Epub 2020 Feb 5. J Gastroenterol Hepatol. 2020. PMID: 31994788